Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Sandostatin® SC
( octreotide acetate )Oncology -
Sandostatin LAR®
( octreotide acetate )Oncology -
Rydapt®
( midostaurin )Oncology -
Ritalin®
( methylphenidate HCl )Neuroscience -
Ritalin LA®
( methylphenidate HCl modified release )NeuroscienceAvailable in -
Promacta®/Revolade®
( eltrombopag )Oncology -
Proleukin®
( aldesleukin )Oncology -
Pluvicto™
( lutetium Lu 177 vipivotide tetraxetan )Advanced Accelerator ApplicationsAvailable in -
Piqray®
( alpelisib )Oncology